Table 3:

Estimated NNV with herpes zoster vaccines to prevent herpes zoster–related events, by age at vaccination

Herpes zoster–related event, by age at vaccination*Type of vaccine; median NNV (90% UI)
Live attenuated vaccineRecombinant subunit vaccine
50 yr
Herpes zoster15 (6–28)7 (5–26)
Ophthalmic herpes zoster103 (34–230)49 (29–193)
Postherpetic neuralgia106 (26–341)36 (22–288)
Hospital admission638 (103–2419)171 (84–2061)
Death71 898 (13 407–2 610 325)19 473 (11 148–2 200 338)
60 yr
Herpes zoster18 (9–28)8 (6–21)
Ophthalmic herpes zoster122 (56–229)54 (34–150)
Postherpetic neuralgia78 (31–150)33 (23–128)
Hospital admission463 (119–1136)149 (84–947)
Death39 072 (14 670–91 623)15 915 (10 625–8621)
65 yr
Herpes zoster21 (13–31)8 (6–18)
Ophthalmic herpes zoster138 (76–285)57 (37–138)
Postherpetic neuralgia64 (33–93)31 (23–73)
Hospital admission335 (124–700)137 (82–613)
Death27 828 (14 354–41 590)13 672 (9865–32 620)
70 yr
Herpes zoster28 (21–43)9 (7–19)
Ophthalmic herpes zoster196 (123–362)65 (43–139)
Postherpetic neuralgia73 (42–96)35 (27–73)
Hospital admission289 (133–494)130 (83–385)
Death32 120 (18 131–43 416)15 753 (11 630–32 797)
75 yr
Herpes zoster42 (32–63)11 (9–19)
Ophthalmic herpes zoster295 (171–586)77 (48–161)
Postherpetic neuralgia78 (51–102)40 (31–71)
Hospital admission215 (126–378)116 (75–226)
Death34 638 (21 718–50 059)18 139 (13 206–32 667)
80 yr
Herpes zoster75 (47–125)14 (11–22)
Ophthalmic herpes zoster523 (257–1136)96 (60–190)
Postherpetic neuralgia97 (68–126)50 (40–80)
Hospital admission269 (169–466)145 (95–267)
Death43 125 (29 410–61 470)22 811 (16 801–37 057)
85 yr
Herpes zoster142 (67–380)18 (15–25)
Ophthalmic herpes zoster983 (377–3133)124 (79–237)
Postherpetic neuralgia124 (94–164)66 (52–94)
Hospital admission351 (229–604)188 (125–328)
Death55 957 (40 079–79 288)29 816 (22 096–44 152)
  • Note: 90% UI = uncertainty interval (based on 5th and 95th percentiles of 30 000 simulation results), NNV = number needed to vaccinate.

  • * Ages shown are individuals’ exact age.